|
UHPLC-MS/MS Single Run Quantification Method for Simultaneous Determination of Triazolopyrazine and N-Nitroso-Triazolopyrazine in Sitagliptin; Risk Assessment, Scavenger-Based Mitigation, and Stress Stability Study -Pub
|
|
0
|
120
|
May 20, 2026
|
|
Liquid Chromatography–High-Resolution Mass Spectrometric Determination of Nitrite Ion Concentration in the Natural Water Resources -Pub
|
|
0
|
102
|
May 20, 2026
|
|
Simultaneous Determination of Duloxetine and N-Nitroso-Duloxetine in Reactor Cleaning Solvent Samples by LC–HRMS: Formation, Quantitation, and Green -Pub
|
|
0
|
152
|
May 20, 2026
|
|
🇰🇷 MFDS Guideline: Compilation of Analysis Methods on the Determination of Impurities in Pharmaceuticals, May-2026
|
|
2
|
354
|
May 19, 2026
|
|
Source of N-nitroso-n-methylaniline (NMPA)
|
|
7
|
384
|
May 19, 2026
|
|
Regulatory Rationale for Restricting LTL Application to Nitrosamines
|
|
4
|
536
|
May 19, 2026
|
|
Analytical challenge for determination of instable standard of other N-nitroso structure
|
|
13
|
1344
|
May 18, 2026
|
|
Science-led approaches to nitrosamine qualification and safety assessment-webinar
|
|
1
|
244
|
May 15, 2026
|
|
N-Nitroso Mefanaminc Acid
|
|
1
|
163
|
May 12, 2026
|
|
Development of an Efficient and Scalable Process for Preparing Timolol N-Nitrosamine Impurities B, C, E, H, I, J, and Their ADMET Evaluation -Pub
|
|
2
|
219
|
May 8, 2026
|
|
Diluent Selection for Nitrosamine Impurities
|
|
7
|
455
|
May 8, 2026
|
|
FDA-CDER and HESI | Nitrosamine Ames Data Review and Method Development Workshop
|
|
2
|
421
|
May 6, 2026
|
|
Generic Drugs Forum (GDF) 2026
|
|
17
|
998
|
May 5, 2026
|
|
Benchmark Dose (BMD) Modeling for Risk Assessment webinar
|
|
1
|
343
|
May 4, 2026
|
|
Adjusting the Preincubation Conditions to Enhance the Ames Test for Detecting the Mutagenicity of N‐Nitrosamines-Pub
|
|
2
|
209
|
May 1, 2026
|
|
Hunt for NDSRIs: Unveiling Hidden Threats with the Novel 15N-Enriched NAP Test-Pub
|
|
3
|
567
|
April 30, 2026
|
|
Early life exposure to N-nitrosamine drives genotoxicity, mutagenesis, and tumorigenesis in DNA repair-deficient mice -Pub
|
|
5
|
513
|
April 30, 2026
|
|
N-Nitroso dially amine estimation by LCMS
|
|
2
|
109
|
April 29, 2026
|
|
N-NO formation in 2-mercaptobenzothiazole
|
|
2
|
155
|
April 29, 2026
|
|
Something in the air−Unveiling the role of atmospheric nitrogen oxides in nitrosamine formation from amine-containing APIs: Mechanistic insights and risk assessment-Pub
|
|
2
|
539
|
April 28, 2026
|
|
Nitrosamine limit in the specification based on intermediate and accelerated stability condition results
|
|
4
|
273
|
April 28, 2026
|
|
How to overcome blank interference at NDBA
|
|
4
|
250
|
April 27, 2026
|
|
🇯🇵 Current Nitrosamine Landscape in Japan?
|
|
186
|
18784
|
April 26, 2026
|
|
Removal of nitrosamine analysis from the specification
|
|
3
|
330
|
April 24, 2026
|
|
Construction of a modified Arrhenius equation for predicting drug nitrosation in solid dosage form -Pub
|
|
4
|
1224
|
April 21, 2026
|
|
Mutagenic and carcinogenic potency determinations for NDMA support the cumulative dose assumption underpinning the less-than-lifetime Threshold of Toxicological Concern -Pub
|
|
0
|
182
|
April 21, 2026
|
|
Kinetic reaction rates for nitrosamine formation using secondary amines pKa
|
|
3
|
430
|
April 21, 2026
|
|
About the amlodipine nitrosamines
|
|
3
|
347
|
April 21, 2026
|
|
EMA's Revision of the Acceptance Limit for N-Nitroso-N-desmethyl-diphenhydramine
|
|
4
|
520
|
April 20, 2026
|
|
Potential for Nitrosamines in Medical Device Combination Products - Letter to Industry(FDA)
|
|
4
|
258
|
April 20, 2026
|